Please select the option that best describes you:
Topics:
Breast Cancer • Radiation Oncology
Do you ever use molecular assays such as Oncotype to modify your recommendations for withholding RT after lumpectomy in invasive breast cancer?
Answer from: Radiation Oncologist at Community Practice
This is part of the ongoing IDEA study. At present, we don't use Oncotype DX information for withholding RT for invasive breast cancer after lumpectomy.
Sign in or Register to read more